Research area
Cancer Immunotherapy
Immune-directed cancer treatments, including therapeutic vaccines and oncolytic approaches. Engineered cell products belong under Cell & Gene Therapy.
-
Evidence date ·Why are researchers looking beyond one immune pathway in head and neck cancer?
Review or Meta-AnalysisA 2025 review surveys four immune targets beyond PD-1/PD-L1 in head and neck cancer. It does not establish patient benefit or the safety of combinations.
-
Evidence date ·Can a replaceable targeting molecule change how engineered T cells fight tumors?
Review or Meta-AnalysisA review of 33 mouse studies found tumor and survival benefits over negative controls. Conventional CAR-T comparisons were inconclusive, and dosing varied.
-
Evidence date ·How faulty DNA repair links uterine-lining cancer treatment with family risk
Review or Meta-AnalysisA February 2024 review explains how tumor testing can guide immunotherapy and reveal inherited risk, while response differences remain unresolved.
-
Evidence date ·How a review connects some Chinese medicine interventions to tumor and immune cells
Review or Meta-AnalysisA 2024 review explains two routes from Chinese-medicine interventions to immune change, from tumor tissue to blood, without proving a patient benefit.
-
Evidence date ·How a DNA-sensing virus helped checkpoint therapy in mouse lung tumors
Peer-Reviewed PaperTracked over timeThree of five mice showed tumor regression with an engineered virus plus PD-L1 blockade. Human safety and tumor selectivity remain unproven.
-
Evidence date ·How a virus used in smallpox vaccines could trigger an immune response beyond a lung tumor
Review or Meta-AnalysisTracked over timeA May 2026 review weighs early clinical findings on vaccinia for lung cancer and the challenges of delivering the virus and sustaining an immune response.
-
Evidence date ·How viruses could link lung cancer cell destruction with an immune response
Review or Meta-AnalysisTracked over timeA 2024 review describes viruses that multiply in cancer cells, break them apart and stimulate immunity; its abstract focuses on rationale, not patient outcomes.
-
Evidence date ·How production shapes a cancer treatment made from a patient’s cells
Review or Meta-AnalysisA January 2024 review explains where time is spent, how cell growth and gene delivery reshape the product, and why safety remains a separate hurdle.
-
Evidence date ·How engineered cytokines redirect immune messages by cell, time and place
Review or Meta-AnalysisA 2023 review explains cytokine engineering for cancer and the unsuccessful clinical test of bempegaldesleukin combined with nivolumab.
-
Evidence date ·Why directing immune signals may matter more than simply increasing them in lymphoma treatment
Review or Meta-AnalysisA 2022 review explains IL-2’s competing effects, what IL-12–rituximab trials reveal, and how targeted or engineered signals might help lymphoma care.